Pathology: mML - L2 - all population; mML - L2 - BRAF mutant;
| mML - L2 - all population | mML - L2 - BRAF mutant | ||||||
| CheckMate 037, 2015 | KEYNOTE-006 (3 week), 2015 | KEYNOTE-002 (10 mg/kg), 2015 | KEYNOTE-006 (2 week), 2015 | KEYNOTE-002 (2 mg/kg), 2015 | KEYNOTE-022, 2019 | ||
| pembrolizumab (10mg/kg) | 2 | T1 | T1 | ||||
| pembrolizumab plus SoC | 1 | T1 | |||||
| nivolumab alone | 1 | T1 | |||||
| pembrolizumab (10mg/kg) 2 weeks | 1 | T1 | |||||
| pembrolizumab (2mg/kg) | 1 | T1 | |||||
| placebo plus SoC | 0 | T0 | |||||
| Standard of Care (SoC) | 0 | T0 | T0 | T0 | |||
| ipilimumab alone | 0 | T0 | T0 | ||||